Page last updated: 2024-10-22

dan 2163 and Mood Disorders

dan 2163 has been researched along with Mood Disorders in 2 studies

Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Hopkins, SC1
Wilkinson, S1
Corriveau, TJ1
Nishikawa, H1
Nakamichi, K1
Loebel, A1
Koblan, KS1
Silvestre, FJ1
Silvestre-Rangil, J1
López-Jornet, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)[NCT03543410]Phase 2344 participants (Actual)Interventional2018-06-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Global Severity Assessed by the Clinical Global Impressions - Severity: Bipolar Version (CGI-BP-S) Score (Depression) at Week 6

Clinical Global Impressions - Severity: Bipolar Version (CGI-BP-S) score (depression) is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill subjects. A higher score is associated with greater illness severity. (NCT03543410)
Timeframe: 6 Weeks

Interventionunits on a scale (Least Squares Mean)
SEP-4199 200 mg-2.020
SEP-4199 400 mg-1.958
Placebo-1.739

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6

MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts, each ranging from 0 to 6. The MADRS total score ranges from 0 to 60, with higher scores indicating increased depressive symptoms (NCT03543410)
Timeframe: 6 Weeks

Interventionunits on a scale (Least Squares Mean)
SEP-4199 200 mg-19.485
SEP-4199 400 mg-19.324
Placebo-16.196

Reviews

1 review available for dan 2163 and Mood Disorders

ArticleYear
Burning mouth syndrome: a review and update.
    Revista de neurologia, 2015, May-16, Volume: 60, Issue:10

    Topics: Adult; Age Distribution; Aged; Algorithms; Amisulpride; Antidepressive Agents; Burning Mouth Syndrom

2015

Trials

1 trial available for dan 2163 and Mood Disorders

ArticleYear
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:3

    Topics: Adult; Amisulpride; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dopamine

2021